Christopher Bowlus
Staff Affiliate - Other
Research & Publications
Biography
Coauthors
Selected Publications
- Protocol for the development of a core outcome set for clinical trials in primary sclerosing cholangitisHussain N, Ma C, Hirschfield G, Walmsley M, Hanford P, Vesterhus M, Kowdley K, Bergquist A, Ponsioen C, Levy C, Assis D, Schramm C, Bowlus C, Trauner M, Aiyegbusi O, Jairath V, Trivedi P. Protocol for the development of a core outcome set for clinical trials in primary sclerosing cholangitis. BMJ Open 2024, 14: e080143. PMID: 38926149, PMCID: PMC11216047, DOI: 10.1136/bmjopen-2023-080143.
- LBP-039 Oral alpha-v/beta-6 and alpha-v/beta-1 integrin inhibitor bexotegrast in primary sclerosing cholangitis: updated 12-week interim safety and efficacy analysis of the INTEGRIS-PSC phase 2a trialTrauner M, Kowdley K, Hirschfield G, Lefebvre E, Decaris M, Schaub J, Clark A, Lin M, An M, Balasubramanyam A, Barnes C, Pencek R, Thorburn D, Montano-Loza A, Bowlus C, Schramm C, Levy C, Trivedi P. LBP-039 Oral alpha-v/beta-6 and alpha-v/beta-1 integrin inhibitor bexotegrast in primary sclerosing cholangitis: updated 12-week interim safety and efficacy analysis of the INTEGRIS-PSC phase 2a trial. Journal Of Hepatology 2024, 80: s97-s98. DOI: 10.1016/s0168-8278(24)00606-8.
- Patient-focused drug development in primary sclerosing cholangitis: Insights on patient priorities and involvement in clinical trialsLi M, Pai R, Gomel R, Vyas M, Callif S, Hatchett J, Bowlus C, Lai J. Patient-focused drug development in primary sclerosing cholangitis: Insights on patient priorities and involvement in clinical trials. Hepatology Communications 2024, 8: e0433. PMID: 38727680, PMCID: PMC11093571, DOI: 10.1097/hc9.0000000000000433.
- Assessment of fatigue and its impact in chronic liver diseaseYounossi Z, Kremer A, Swain M, Jones D, Bowlus C, Trauner M, Henry L, Gerber L. Assessment of fatigue and its impact in chronic liver disease. Journal Of Hepatology 2024 PMID: 38670320, DOI: 10.1016/j.jhep.2024.04.008.
- Impact of itch on quality of life in people with primary biliary cholangitis: A plain language summaryMayo M, Carey E, Smith H, Mospan A, McLaughlin M, Thompson A, Morris H, Sandefur R, Bowlus C, Investigators O, Levy C. Impact of itch on quality of life in people with primary biliary cholangitis: A plain language summary. Future Rare Diseases 2024, 0 DOI: 10.2217/frd-2023-0016.
- A Phase 3 Trial of Seladelpar in Primary Biliary CholangitisHirschfield G, Bowlus C, Mayo M, Kremer A, Vierling J, Kowdley K, Levy C, Villamil A, Ladrón de Guevara Cetina A, Janczewska E, Zigmond E, Jeong S, Yilmaz Y, Kallis Y, Corpechot C, Buggisch P, Invernizzi P, Londoño Hurtado M, Bergheanu S, Yang K, Choi Y, Crittenden D, McWherter C. A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis. New England Journal Of Medicine 2024, 390: 783-794. PMID: 38381664, DOI: 10.1056/nejmoa2312100.
- Per-oral cholangioscopy in patients with primary sclerosing cholangitis: a 12-month follow-up studyMohamed R, Tejaswi S, Aabakken L, Ponsioen C, Bowlus C, Adler D, Forbes N, Paulsen V, Voermans R, Urayama S, Peetermans J, Rousseau M, Eksteen B. Per-oral cholangioscopy in patients with primary sclerosing cholangitis: a 12-month follow-up study. Endoscopy International Open 2024, 12: e237-e244. PMID: 38362361, PMCID: PMC10869209, DOI: 10.1055/a-2236-7557.
- Hypercholesterolemia Is Associated With Dysregulation of Lipid Metabolism and Poor Prognosis in Primary Biliary CholangitisZheng L, Tian S, Yang C, Li B, Jia G, Liu Y, Sun R, Wang X, Deng J, Zhang M, Cui L, Guo C, Zhou X, Leung P, Bowlus C, Gershwin M, Shang Y, Han Y. Hypercholesterolemia Is Associated With Dysregulation of Lipid Metabolism and Poor Prognosis in Primary Biliary Cholangitis. Clinical Gastroenterology And Hepatology 2024, 22: 1265-1274.e19. PMID: 38354969, DOI: 10.1016/j.cgh.2024.01.039.
- African American race does not confer an increased risk of clinical events in patients with primary sclerosing cholangitis.Yazdanfar M, Zepeda J, Dean R, Wu J, Levy C, Goldberg D, Lammert C, Prenner S, Reddy K, Pratt D, Forman L, Assis D, Lytvyak E, Montano-Loza A, Gordon S, Carey E, Ahn J, Schlansky B, Korzenik J, Karagozian R, Hameed B, Chandna S, Yu L, Bowlus C. African American race does not confer an increased risk of clinical events in patients with primary sclerosing cholangitis. Hepatology Communications 2024, 8 PMID: 38285883, PMCID: PMC10830082, DOI: 10.1097/hc9.0000000000000366.
- Featured CoverMayo M, Vierling J, Bowlus C, Levy C, Hirschfield G, Neff G, Galambos M, Gordon S, Borg B, Harrison S, Thuluvath P, Goel A, Shiffman M, Swain M, Jones D, Trivedi P, Kremer A, Aspinall R, Sheridan D, Dörffel Y, Yang K, Choi Y, McWherter C. Featured Cover. Alimentary Pharmacology & Therapeutics 2023, 59: i-i. DOI: 10.1111/apt.17864.
- Editorial: The evolving paradigms and treatments for primary biliary cholangitis—Authors' replyMayo M, Vierling J, Bowlus C. Editorial: The evolving paradigms and treatments for primary biliary cholangitis—Authors' reply. Alimentary Pharmacology & Therapeutics 2023, 59: 282-282. PMID: 38153281, DOI: 10.1111/apt.17798.
- Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitisKremer A, Mayo M, Hirschfield G, Levy C, Bowlus C, Jones D, Johnson J, McWherter C, Choi Y. Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis. Hepatology 2023, 80: 27-37. PMID: 38117036, PMCID: PMC11191048, DOI: 10.1097/hep.0000000000000728.
- Efficacy and Safety of Elafibranor in Primary Biliary CholangitisKowdley K, Bowlus C, Levy C, Akarca U, Alvares-da-Silva M, Andreone P, Arrese M, Corpechot C, Francque S, Heneghan M, Invernizzi P, Jones D, Kruger F, Lawitz E, Mayo M, Shiffman M, Swain M, Valera J, Vargas V, Vierling J, Villamil A, Addy C, Dietrich J, Germain J, Mazain S, Rafailovic D, Taddé B, Miller B, Shu J, Zein C, Schattenberg J. Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis. New England Journal Of Medicine 2023, 390: 795-805. PMID: 37962077, DOI: 10.1056/nejmoa2306185.
- Open‐label, clinical trial extension: Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitisMayo M, Vierling J, Bowlus C, Levy C, Hirschfield G, Neff G, Galambos M, Gordon S, Borg B, Harrison S, Thuluvath P, Goel A, Shiffman M, Swain M, Jones D, Trivedi P, Kremer A, Aspinall R, Sheridan D, Dörffel Y, Yang K, Choi Y, McWherter C. Open‐label, clinical trial extension: Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitis. Alimentary Pharmacology & Therapeutics 2023, 59: 186-200. PMID: 37904314, DOI: 10.1111/apt.17755.
- YIELD OF EARLY PER-ORAL CHOLANGIOSCOPY IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITISMohamed R, Forbes N, Aabakken L, Paulsen V, Ponsioen C, Voermans R, Tejaswi S, Bowlus C, Urayama S, Adler D, Peetermans J, Rousseau M, Eksteen B. YIELD OF EARLY PER-ORAL CHOLANGIOSCOPY IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS. Gastrointestinal Endoscopy 2023, 97: ab592. DOI: 10.1016/j.gie.2023.04.979.
- EPH110 Structured Literature Review of Evidence on the Clinical, Humanistic, and Economic Burden of Primary Sclerosing CholangitisLevy C, Bowlus C, Kachru N, Ammirabile G, Walker S, Alleman C, Kowdley K. EPH110 Structured Literature Review of Evidence on the Clinical, Humanistic, and Economic Burden of Primary Sclerosing Cholangitis. Value In Health 2023, 26: s184. DOI: 10.1016/j.jval.2023.03.992.
- EE59 Development and Validation of the Natural History Component of an Economic Model for Primary Sclerosing CholangitisBowlus C, Levy C, Kowdley K, Kachru N, Kaushik A, Jeyakumar S, Rodriguez-Guadarrama Y, Smith N, Briggs A, Sculpher M, Ollendorf D. EE59 Development and Validation of the Natural History Component of an Economic Model for Primary Sclerosing Cholangitis. Value In Health 2023, 26: s70. DOI: 10.1016/j.jval.2023.03.364.
- EPH84 Administrative Claims-Based Algorithm to Identify Patients with Primary Sclerosing CholangitisKowdley K, Levy C, Kachru N, Kaushik A, Grossman A, Wong A, Veeranki P, Bowlus C. EPH84 Administrative Claims-Based Algorithm to Identify Patients with Primary Sclerosing Cholangitis. Value In Health 2023, 26: s179. DOI: 10.1016/j.jval.2023.03.966.